Correlation between LncRNA SNHG10 and METTL3 in colorectal cancer

  • ZHAO Shengjie ,
  • LI Ruibin ,
  • WAN Zhiheng
Expand
  • The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou 014010, China

Received date: 2024-07-22

  Online published: 2025-03-26

Abstract

Objective: To study the expression of lncRNA SNHG10 and methyltransferase METTL3 in colorectal cancer (CRC) tissues and adjacent tissues. Meanwhile, to explore the potential relationship between lncRNA SNHG10 and METTL3 in CRC. Methods: Tumor tissue and paracancerous tissue samples of 15 CRC patients were collected. The expression of lncRNA SNHG10 and METTL3 in CRC was investigated by bioinformatics, real-time fluorescence quantitative PCR (RT-qPCR) and Western blot. The relationship between the relative expression level of lncRNA SNHG10 in colorectal cancer and prognosis was analyzed. The gene interaction was analyzed by TCGA database, ENCORI, cBioPortal website and in vitro inhibition experiment of colon cancer cell line (HCT116). Results: Bioinformatics website and RT-qPCR experiments showed that lncRNA SNHG10 was up-regulated in colorectal cancer compared with adjacent tissues (P<0.05). The high expression of lncRNA SNHG10 indicated that CRC patients were more likely to have lymph node metastasis, and the disease-specific survival rate and overall survival rate were relatively low (P<0.05). RT-qPCR and Western blot results confirmed that METTL3 was highly expressed in CRC tumor tissues. In vitro experiments showed that knockdown of lncRNA SNHG10 in HCT116 cells resulted in down-regulation of METTL3 expression at both mRNA and protein levels (P<0.05). Conclusion: The high expression of lncRNA SNHG10 is associated with tumor progression and poor prognosis. LncRNA SNHG10 is positively correlated with METTL3 and regulates METTL3 expression. This study suggests that SNHG10 may be a promising CRC biomarker and therapeutic target.

Cite this article

ZHAO Shengjie , LI Ruibin , WAN Zhiheng . Correlation between LncRNA SNHG10 and METTL3 in colorectal cancer[J]. Journal of Baotou Medical College, 2025 , 41(3) : 41 -47 . DOI: 10.16833/j.cnki.jbmc.2025.03.008

References

[1] Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040[J]. Transl Oncol,2021,14(10):101174.
[2] Brody H. Colorectal cancer[J]. Nature,2015,521(7551):S1.
[3] Wei W, Zeng H, Zheng R, et al. Cancer registration in China and its role in cancer prevention and control[J]. Lancet Oncol, 2020,21(7):e342-e349.
[4] Li C, Sun YD, Yu GY, et al. Integrated omics of metastatic colorectal cancer[J]. Cancer Cell, 2020,38:734-47. e9.
[5] Bridges MC, Daulagala AC, Kourtidis A. LNCcation: lncRNA localization and function[J]. J Cell Biol,2021,220(2):e202009045.
[6] Lan T, Yuan K, Yan X, et al. LncRNA SNHG10 Facilitates Hepatocarcinogenesis and Metastasis by Modulating Its Homolog SCARNA13 via a Positive Feedback Loop[J]. Cancer Res, 2019,79(13):3220-3234.
[7] Zhang Y, Guo H, Zhang H. SNHG10/DDX54/PBX3 Feedback Loop Contributes to Gastric Cancer Cell Growth[J]. Dig Dis Sci,2021,66(6):1875-1884.
[8] Lv W, Jia Y, Wang J, et al. Long non-coding RNA SNHG10 upregulates BIN1 to suppress the tumorigenesis and epithelial-mesenchymal transition of epithelial ovarian cancer via sponging miR-200a-3p[J]. Cell Death Discov,2022,8(1):60.
[9] Aini S, Bolati S, Ding W, et al. LncRNA SNHG10 suppresses the development of doxorubicin resistance by downregulating miR-302b in triple-negative breast cancer[J]. Bioengineered,2022,13(5):11430-11439.
[10] Chan JJ, Tay Y. Noncoding RNA:RNA regulatory networks in cancer[J]. Int J Mol Sci,2018,19:1310.
[11] Yuan X, Yang T, Xu Y, et al. SNHG10 Promotes Cell Proliferation and Migration in Gastric Cancer by Targeting miR-495-3p/CTNNB1 Axis[J]. Dig Dis Sci,2021,66(8):2627-2636.
[12] Wei Y, Li Y, Lu C. Exploring the role of m6A modification in cancer[J]. Proteomics,2023,23(13-14):e2200208.
[13] Xu Y, Bao Y, Qiu G, et al. METTL3 promotes proliferation and migration of colorectal cancer cells by increasing SNHG1 stability[J]. Mol Med Rep,2023,28(5):217.
[14] Li H, Liu Z, Wang H. Expression and clinical significance of METTL3 in colorectal cancer[J]. Medicine (Baltimore),2023,102(37):e34658.
[15] Zhang H, Fang Z, Guo Y, et al. Long noncoding RNA SNHG10 promotes colorectal cancer cells malignant progression by targeting miR-3690[J]. Bioengineered,2021,12(1):6010-6020.
[16] Huang Y, Luo Y, Ou W, et al. Exosomal lncRNA SNHG10 derived from colorectal cancer cells suppresses natural killer cell cytotoxicity by upregulating INHBC [J]. Cancer Cell Int,2021,21(1):528.
[17] Chen H, Gao S, Liu W, et al. RNA N6-Methyladenosine Methyltransferase METTL3 Facilitates Colorectal Cancer by Activating the m6A-GLUT1-mTORC1 Axis and Is a Therapeutic Target [J].Gastroenterology,2021,160(4):1284-1300.e16.
[18] Wei X, Huo Y, Pi J, et al. METTL3 preferentially enhances non-m6A translation of epigenetic factors and promotes tumourigenesis[J]. Nat Cell Biol,2022,24(8):1278-1290.
[19] Yankova E, Blackaby W, Albertella M, et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia[J]. Nature,2021,593(7860):597-601.
[20] Pan J, Liu F, Xiao X, et al. METTL3 promotes colorectal carcinoma progression by regulating the m6A-CRB3-Hippo axis[J]. J Exp Clin Cancer Res,2022,41(1):19.
Outlines

/